US EditionAkeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
- Akeso Inc. Presented promising results from the Phase III COMPASSION-18 study at the 2025 Annual Meeting of the Society of Gynecologic Oncology, showing cadonilimab's efficacy with concurrent chemoradiotherapy in locally advanced cervical cancer patients.
- The study achieved an overall response rate of 100%, with a complete response rate of 84.8%, which outperformed other studies.
- Cadonilimab has a favorable safety profile, with no treatment-related deaths reported, and is currently under regulatory review for use as a first-line treatment for advanced cases.
- The results indicate cadonilimab's potential to improve treatment outcomes for locally advanced cervical cancer, establishing it as a significant option in therapy.
Insights by Ground AI
Does this summary seem wrong?
68 Articles
68 Articles
All
Left
6
Center
25
Right
8
The Berkshire Eagle+66 Reposted by 66 other sources
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4…
Coverage Details
Total News Sources68
Leaning Left6Leaning Right8Center25Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
15%
C 64%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
